89bio, Inc/ETNB

$8.12

1.25%
-
1D1W1MYTD1YMAX

About 89bio, Inc

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.

Ticker

ETNB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Rohan Palekar

Employees

70

Headquarters

San francisco, United States

89bio, Inc Metrics

BasicAdvanced
$819M
Market cap
-
P/E ratio
-$2.01
EPS
1.01
Beta
-
Dividend rate
$819M
1.00824
$22.93
$6.58
1M
15.031
4.518
4.888
-30.8%
-34.51%
-32.7%
1.551
1.603
28.8%

What the Analysts think about 89bio, Inc

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 9 analysts.
284.48% upside
High $50.00
Low $13.00
$8.12
Current price
$31.22
Average price target

89bio, Inc Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$52M
28.36%
Profit margin
0%
NaN%

89bio, Inc Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 17.07%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.52
-$0.45
-$0.50
-$0.54
-
Expected
-$0.41
-$0.53
-$0.50
-$0.46
-$0.57
Surprise
26.39%
-15.09%
1.01%
17.07%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for 89bio, Inc stock?

89bio, Inc (ETNB) has a market cap of $819M as of May 30, 2024.

What is the P/E ratio for 89bio, Inc stock?

The price to earnings (P/E) ratio for 89bio, Inc (ETNB) stock is 0 as of May 30, 2024.

Does 89bio, Inc stock pay dividends?

No, 89bio, Inc (ETNB) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next 89bio, Inc dividend payment date?

89bio, Inc (ETNB) stock does not pay dividends to its shareholders.

What is the beta indicator for 89bio, Inc?

89bio, Inc (ETNB) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the 89bio, Inc stock price target?

The target price for 89bio, Inc (ETNB) stock is $31.22, which is 284.48% above the current price of $8.12. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell 89bio, Inc stock

Buy or sell 89bio, Inc stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing